Apollo HospitalsQ4 FY25

Apollo Hospitals Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹8,712.5P/E: 55.3Market Cap: ₹1.3L CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • Pharmacy front-end business expected to grow over 20% in FY '26 and beyond.
  • Digital business (Apollo 24/7) targeting 25%-30% GMV growth annually; aiming for INR 1,000 crore GMV to breakeven.
  • Apollo HealthCo revenues grew 17% YoY in Q4, supported by omnichannel pharmacy and double-digit GMV growth; aiming to hit around INR 24,000 to 25,000 crore by FY '27.
  • Diagnostics business targeting 2%-3% margin improvement this year; aiming for 20% EBITDA margin in next 2-3 years with volume growth through lab expansions.
  • Apollo Pharmacy aims to increase market share from current 8% to 20% in 5-6 years by adding 600 stores annually and expanding to new geographies.
  • Specialty clinics and primary care clinics expected to grow in high teens.
  • Digital insurance business started contributing; expected to grow significantly next year.
  • New hospitals and bed additions planned, with operational expansion in Q3/Q4 FY '26 enhancing volumes and revenues.

See what Apollo Hospitals management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The transcript provided from the earnings call does not mention any specific current or future plans for fundraising through debt or equity.
  • The company highlights having significant cash and cash equivalents on hand and generating healthy free cash flows in excess of INR 1,000 crore per year after routine items.
  • It mentions confidence in funding portfolio expansion (INR 6,000 crore over 3-4 years) primarily through existing funds and internal accruals, without indicating the need for additional fundraising.
  • No direct references to new debt issuance or equity raising initiatives were found on the discussed pages.

See what Apollo Hospitals management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Apollo Hospitals is committed to spending over INR 8,000 crore for adding 4,300 beds over the next 3 to 4 years.
  • INR 1,000 crore has already been spent on land acquisition and project development; the balance INR 6,000 crore will be spent over the next 3 to 4 years.
  • Key projects include operationalizing facilities in Gurgaon, Pune, Kolkata, Hyderabad, and significant expansion in Bangalore's Sarjapur area with 700 additional beds via acquisition and greenfield development.
  • Expansion also planned in Jubilee Hills, Secunderabad, and Gachibowli Hyderabad, boosting overall bed strength to 1,500 in Hyderabad and Bangalore.
  • Apollo HealthCo is advancing the Keimed merger with 15 months timeline for completion.
  • New insurance partnerships for Apollo 24/7 are expected to drive revenue, with no losses anticipated this fiscal year but significant margin increases expected next year.
  • No intention to tie up with quick commerce platforms; focus remains on building in-house digital capabilities.

Track Apollo Hospitals — get its next earnings analysis in your feed

How does Apollo Hospitals rank vs peers in Healthcare Services?

Pro feature
ThisApollo Hospitals
Rev 2Mar 1

How does Apollo Hospitals rank in Healthcare Services?

Compare Apollo Hospitals against every Healthcare Services company (Q4 FY25) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →